Another rare cannabis compound is offering a big profit opportunity…

While 2019 was the Year of CBD, we told you right before the new year that 2020 was going to be the rise of THCV and CBN.

That’s why, when InMed Pharmaceuticals Inc. (OTC: IMLFF) announced that it was using CBN as an active pharmaceutical ingredient (API) in two product candidates under development, we weren’t surprised.

As a quick refresher, CBN is a rare cannabinoid that is only found in trace amounts in the cannabis plant. Scientists are still studying its healing properties, but early results look promising.

“We are proud to be the first company to investigate cannabinol’s therapeutic potential in human clinical trials. InMed has completed more than 30 preclinical pharmacology and toxicology studies, identifying potential therapeutic advantages of CBN in specific disease models over the more common cannabinoids THC and CBD, as well as other rare variants,” InMed CEO Eric Adams said in a statement.

[LEARN HOW TO ACCESS NOW] Find out what InMed is rated today and see for yourself whether it’s worth your hard-earned cash with access to the most comprehensive cannabis stock database on the planet, the “Marijuana Millionaire’s Vault.”

One of its products – INM-755 – is being developed to treat a rare genetic skin disease.

Its other product – INM-088 – could potentially treat ocular disease.

This is great news for the expansion of cannabis-based medicine.

But aside from utilizing more compounds to heal people, there’s something else about this process that we’re watching closely…

The Future of Cannabis-Based Medicine

The Tufts Center for the Study of Drug Development estimated that it costs drugmakers $2.6 billion to develop a new prescription medicine that gains marketing approval.

Clinical trials alone can take six to seven years, which means it’s a very lengthy and expensive process to get a drug to market.

But InMed has an advantage thanks to its biosynthesis and bioinformatics technologies.

“We are simultaneously exploring innovative biosynthetic manufacturing methods and therapeutic applications of CBN formulations to target diseases with high unmet medical need,” InMed’s CEO said.

And that biosynthetic manufacturing comment is important.

It’s something Executive Director Don Yocham recently wrote about.

“In my view, looking 10 years down the road, most cannabinoids will be sourced through biosynthesis. It’s the only way to produce trace cannabinoids economically, and it’s the cheapest way to produce THC and CBD isolates essential for high-quality cannabis-infused edibles.”

So, as we see the rise of cannabis compounds being utilized in medicine, there will also be a massive need for biosynthesis.

It goes hand-in-hand with uncovering the full potential of the cannabis plant.

For InMed, it could provide contract manufacturing for other pharmaceutical companies as they further develop the ability to create specific cannabinoids.

To be clear, though, this is not a recommendation of InMed.

Rather, we wanted to illustrate the important role biosynthesis is playing because there will be other, better companies capitalizing on the wealth creation from mass-producing rare cannabis compounds.

Discover the companies using biosynthesis that have already made their way into our database, see how they rank, and unlock hundreds of other potential winners today with the “Marijuana Millionaire’s Vault.”

P.S. You can learn all about the proprietary rating system we use to rank the hundreds of cannabis companies contained in the “Vault” – otherwise known as NICILytics – in our free primer, “NICILytics Ratings Explained.”


Comments

4 responses to “Creation of Cannabis Compounds Offers Road to Massive Profits”

  1. I took your advice on canopy and sold all . I bought it in year 17 so I have taken out my profit a couple of times and bought into others with that so my canopy corp shares were free, it was hard to let go, but the 90.000 profit feels good, Had tied most of my money up in stocks, mainly 5s so I am following all advice. life at 80 is exiting since becoming a lifetime member at the beginning. So glad I joined

Leave a Reply

Your email address will not be published. Required fields are marked *